{
    "nctId": "NCT05750693",
    "briefTitle": "PIK3CA in HER2+ BC and pCR Trial",
    "officialTitle": "Impact of Somatic PIK3CA Mutations on Pathological Complete Response (pCR) in HER2-positive Early Breast Cancer.",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "HER2-positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 58,
    "primaryOutcomeMeasure": "pathologic complete response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent.\n* Age older than 18 years.\n* Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy.\n* Tumor lesion in the breast with a palpable size of \u2265 2 cm and/or \u2265 1.5 cm by ultrasound or magnetic resonance imaging (MRI). In case of inflammatory carcinoma the extent of inflammation can be used as measurable lesion.\n* American Joint Commission on Cancer stage II or III invasive breast cancer.\n* Known estrogen (ER)- and progesterone (PgR)-receptor negative or positive tumors.\n* Known HER-2/neu positive tumors, defined as HercepTest IHC 3+ or SISH+.\n* Patients suitable for neoadjuvant chemotherapy\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) \u22642 or Karnowsky performance status index at least 80%.\n* Normal cardiac function must be confirmed by ECG and cardiac ultrasound (LVEF or shortening fraction) within 1 month prior to registration.\n* Laboratory requirements:\n\n  * Hematology: Absolute neutrophil count (ANC) \u2265 1.5 x 109/L, platelets \u2265 100 x 109/L, Hemoglobin \u2265 10 g/dL.\n  * Hepatic function: Total bilirubin \\< 1 x UNL, ASAT (SGOT) and ALAT (SGPT)\u2264 2.5 x UNL, Alkaline phosphatase \u2264 5 UNL. Patients with ASAT and / or ALAT \\> 1.5 x UNL associated with alkaline phosphatase \\> 2.5 x UNL are not eligible for the study.\n  * Renal function: Creatinine \u2264 2 mg/dL, \\< 1,25 UNL (or the calculated creatinine clearance \u2265 60 mL/min).\n  * Paraffin tumor tissue block made available.\n  * Availability to provide the set up of the histological preparations for molecular analysis.\n  * Negative pregnancy test (urine or serum).\n  * Patients must be available and compliant for treatment and follow-up.\n\nExclusion Criteria:\n\n* Patients candidate for adjuvant chemotherapy.\n* Evidence of distant metastasis.\n* Prior chemotherapy for any malignancy.\n* Prior radiation therapy for breast cancer.\n* Pregnant or lactating patients.\n* Inadequate general condition.\n* Previous malignant disease.\n* Known or suspected congestive heart failure (\\>NYHA I) and/or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, un- or poorly controlled arterial hypertension, rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease.\n* History of significant neurological or psychiatric disorders that would prohibit the understanding and giving of informed consent.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}